Join us July 23–25 in Orlando, Florida for a powerful weekend dedicated to support, education and advocacy at the Your Weight Matters National Convention, hosted by the Obesity Action Coalition (OAC).
This energizing weekend brings together individuals, families, healthcare professionals and leading experts for engaging sessions on weight, health, nutrition, mental well-being and treatment options. Discover the latest science, gain practical tools you can use in everyday life and connect with a community that truly understands.
From inspiring speakers and interactive workshops to the lively Health Hub and meaningful conversations with others on a similar journey, every moment is designed to help you learn, connect and feel supported.
Connect with others who understand the challenges of weight and health in a welcoming, judgment-free community.
Expert-led sessions on obesity science, treatment options, nutrition and long-term weight management.
Learn how your voice can help improve access to obesity care and reduce weight bias in healthcare.
Lilly is a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." But we’re not only dedicated to making medicines. We go beyond medicine to deliver innovative clinical trials that reflect the diversity of our world and continue to work to ensure our medicines are accessible and affordable.
We refuse to accept the status quo for people living with serious chronic diseases. For more than century, we have translated unmet medical needs into innovative medicines and delivery systems, like our insulin pens, and today we continue to reimagine what’s possible through bold science.
From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to people living with diabetes, obesity, and rare blood and endocrine diseases around the world.
We don’t take shortcuts… we’re in it for lifeWe’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our distinctive mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Because we believe it takes a dedicated approach to drive real, lasting change in health.
Founded in Denmark in 1923, today we employ more than 69,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.
Amgen's legacy in cardiometabolic disease has provided a foundation of genetic research and a clinical trial infrastructure that has powered the company’s obesity and related conditions pipeline. More information on Amgen’s approach to obesity and related conditions research can be found at Amgen.com/obesity
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for MASH, a serious liver disease with high unmet medical need.
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Genentech is a leading biotechnology company committed to advancing science to improve people’s lives. Through its Giving and Social Impact efforts, Genentech supports initiatives that expand access to healthcare, advance health equity, and empower patients and communities. Their work helps ensure individuals have the resources, education, and support they need to better understand and manage their health.
Our approach seeks to expand upon proven science to advance product candidates which have the potential to maximize weight loss and address critical needs.
Revolutionary medicines enables us to enrich and extend life for people living with all types of diseases
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development.
Patients lie at the heart of our collective mission. They represent our why and breathe life into the work we do. Patient needs and experience shape and inform our entire process from day one in the drug discovery process. It’s a privilege to advance the latest scientific breakthroughs with the goal of alleviating disease burden for patients through the development of more accessible oral small molecule therapeutics.
We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Denmark, with a U.S. presence in Massachusetts.
Bariatric Advantage is committed to the patients, surgeons, support groups and other allied medical professionals who have dedicated their careers to helping improve the lives of patients affected with obesity. Our philosophy is simple: gather scientific data, provide this data to medical and nutritional experts for their review and analysis, then use this process to guide us in our development of unique nutritional supplements. Finally, we measure and publish the results of the patient experience scientifically through lab and other related tests.
Endura Weight Loss Solutions is a brand within Boston Scientific used to describe a category of non-surgical weight loss options. Endura Weight Loss Solutions is a range of non-surgical weight loss procedures done endoscopically—with a small, flexible scope passed gently through your mouth and into your stomach—providing proven weight loss results when paired with diet and lifestyle changes.
Currax Pharmaceuticals is a specialty pharmaceutical company dedicated to advancing the understanding and treatment of chronic progressive diseases. Through its growing portfolio of therapies, Currax partners with healthcare professionals to help address complex patient needs and support improved long-term health outcomes. With a focus on innovation, education, and patient-centered care, Currax is committed to empowering people to live healthier, more fulfilling lives.
Fractyl Health is a clinical stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Wondr is a year-long, skills-based digital weight loss program that helps participants feel their best mentally and physically through simple, clinically-proven techniques and tools. Participants will learn how to enjoy their favorite foods and still lose weight, sleep better, stress less, and more.
Stay Informed about the Your Weight Matters National Convention!
Sign up for exclusive updates on the upcoming Convention, including early registration details, room block availability, speaker announcements, program highlights and more.
